Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant
(XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20 …

Multidrug-resistant tuberculosis (MDR-TB) accounts for one third of the annual deaths due to
antimicrobial resistance. Drug resistance-conferring mutations frequently cause fitness costs …

BACKGROUND: Graft patency is the postulated mechanism for the benefits of coronary
artery bypass grafting (CABG). However, systematic graft imaging assessment after CABG is …

Importance Conventional meta-analyses with aggregated study-level data have yielded
conflicting results for the comparative effectiveness of tenofovir disoproxil fumarate vs …

Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

Abstract Background We evaluated Nix-TB trial data (NCT02333799, N= 109) to provide
dosing recommendations to potentially minimize linezolid toxicity in patients with extensively …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …

Background Multidrug-resistant tuberculosis had high treatment failure and mortality.
Success rate of treatment currently 56% at global level, 48% in Indonesia and 36% in West …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

The care cascade—which evaluates outcomes across stages of patient engagement in a
health system—is an important framework for assessing quality of tuberculosis (TB) care. In …